| Active ingredient (INN) | Bevacizumab |
|---|---|
| Brand names | Zirabev |
| ATC level 5 | L01FG01 |
| ATC level 4 | L01FG |
| Therapeutic category | Auto-created by European Medicines Agency — Medicines Shortages scraper |
| Controlled substance | No |
| Marketing-authorisation holders | Amgen Australia Pty Ltd, Cipla Australia Pty Ltd, Samsung Bioepis AU Pty Ltd, Pfizer Australia Pty Ltd |
| Registrations on file | 14 |
| Patient information leaflet (PIL) | Not on file |
| Summary of product characteristics (SPC) | Not on file |
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| MVASI bevacizumab | 100 mg | — | 🇦🇺 AU | Amgen Australia Pty Ltd | Active |
| MVASI bevacizumab | 400 mg | — | 🇦🇺 AU | Amgen Australia Pty Ltd | Active |
| ABEVMY bevacizumab | 100 mg | — | 🇦🇺 AU | — | Active |
| ABEVMY bevacizumab | 400 mg | — | 🇦🇺 AU | — | Active |
| BEVACIP bevacizumab | 400 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| BEVACIPTIN bevacizumab | 100 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| BEVACIPTIN bevacizumab | 400 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| BEVACIP bevacizumab | 100 mg | — | 🇦🇺 AU | Cipla Australia Pty Ltd | Active |
| ONBEVZI bevacizumab | 100 mg | — | 🇦🇺 AU | Samsung Bioepis AU Pty Ltd | Active |
| VEGZELMA bevacizumab | 100 mg | — | 🇦🇺 AU | — | Active |
| ONBEVZI bevacizumab | 400 mg | — | 🇦🇺 AU | Samsung Bioepis AU Pty Ltd | Active |
| VEGZELMA bevacizumab | 400 mg | — | 🇦🇺 AU | — | Active |
| ZIRABEV bevacizumab | 400 mg | — | 🇦🇺 AU | Pfizer Australia Pty Ltd | Active |
| ZIRABEV bevacizumab | 100 mg | — | 🇦🇺 AU | Pfizer Australia Pty Ltd | Active |